Specttrum News: Poly Medicure Limited, manufacturers of medical devices and disposables under the brand name Polymed, is foraying into Respiratory, Renal and Blood Banking sector.


The Rs 394 crore company, Polymed plans to tap the domestic and international market in a big way with their state-of-the-art technology and quality products.

 

Hemant Bhalla, VP-Sales & Marketingwhile addressing the media in Ludhiana said, The Renal, Respiratory and Blood Banking markets are rapidly growing in India. The market has grown robustly in past few years to become the potential investment field for players. Various factors such as prevalence of diseases, alarming rise in levels of pollution, sedentary lifestyle, poor food habits and increasing penetration of health insurance have contributed substantially to spur demand for these services in the country."

 

Starting with Ludhiana, Polymed plans to introduce advanced range of Respiratory care products, Renal care products including machines, Blood Banking including equipments machine and DEHP & PVC free products to the portfolio to provide better patient care in all major cities of Punjab region including Chandigarh, Jalandhar and Amritsar. 

 

Poly Medicure Ltd is one of the leading medical devices manufacturer and exporter in India with dominant position in medical devices market with focus on innovation, safety and quality and have a vision to provide highest quality of healthcare available to all. POLYMED have 6 manufacturing facilities - 4 in India (2 facilities in Faridabad and 1 in Jaipur and 1 in Haridwar), 2 facilities overseas (One facility in China – wholly owned subsidiary and 1 Joint Venture in Egypt).

 

The company has over 400,000 square feet manufacturing area with 100,000 + square feet clean room area and state of the art facilities with capacity to expand rapidly. The company is proposing to invest Rs. 60 crore  - through Internal accrualand borrowing- in a new green field project at IMT Faridabad in Haryana is geared up to launch a slew of products in 3rd quarter of 2017 with all statutory approvals.